7月29日的ASCP Conference应用程序分析

The 2026 ASCP Annual Meeting is the premier meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies, and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Program Committee for the Annual Meeting chaired by Drs. Mark Rapaport and Tiffany Farchione including representatives from the ASCP Community, FDA, EMA, NIMH, NIDA, NIAAA, and academia members, lead the direction of the meeting. The Review Subcommittee, under the leadership of Drs. Manish Jha and Carlos Blanco, are responsible for the review of all program submissions. To ensure the meeting includes the needs of our loyal pharmaceutical industry members, we are excited to announce the launch of the ASCP Industry Advisory Council led by Drs. Ross Baker and Julie Adams.